Skeletal Dysplasia | Market Size, Share & Growth Report 2025-2034
The Skeletal Dysplasia Market Report is Segmented by Type (Achondroplasia, Osteogenesis Imperfecta, Hypochondroplasia, Thanatophoric Dysplasia, and Multiple Epiphyseal Dysplasia), Diagnosis (Genetic Testing, Imaging Techniques, Biochemical Tests, and Prenatal Screening), Treatment (Medication, Physical Therapy, Surgery, Assistive Devices, and Gene Therapy), End-User (Hospitals, Specialty Clinics, and Research Institutes).
Skeletal Dysplasia Market
Market Analysis
How the market stands today, and what is shaping it
The global skeletal dysplasia market was estimated at approximately USD 3.50 billion in 2025 and is projected to reach around USD 5.91 billion by 2034, representing a CAGR of approximately 6.00% during 2025-2034, based on Core Market Research estimates. The market covers achondroplasia, osteogenesis imperfecta, hypochondroplasia, thanatophoric dysplasia and multiple epiphyseal dysplasia, across genetic testing, imaging, medication, surgery, physical therapy and assistive devices. Growth rests on targeted achondroplasia drugs, from BioMarin's Voxzogo to Ascendis Pharma's once-weekly Yuviwel, and on extension into hypochondroplasia. Expansion is constrained by the absence of an approved targeted drug for osteogenesis imperfecta after setrusumab's Phase 3 setback, and by reimbursement reviews still under way in England and Brazil. BioMarin, Ascendis Pharma, BridgeBio, Ultragenyx and Tyra Biosciences compete on dosing burden, growth effect and indication breadth. North America is the largest region on a publisher assessment, and BridgeBio's oral infigratinib, with filings planned for the second half of 2026, could add a non-injectable option.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Achondroplasia occurs in 1 in 15,000 to 40,000 newborns, according to MedlinePlus, and about 80 percent of cases arise from new FGFR3 variants in children of average-height parents. Each birth cohort therefore adds patients eligible for growth treatment while their growth plates remain open.
- Dosing is moving beyond Voxzogo's daily injection. Ascendis Pharma's Yuviwel is injected once weekly, and BridgeBio's oral infigratinib improved annualized height velocity by 1.74 cm/year over placebo in the Phase 3 PROPEL 3 trial, offering families less burdensome options than daily injections.
- Accelerated approval has opened the achondroplasia market on growth-velocity evidence. The FDA approved Voxzogo in November 2021, extended it to children under 5 in October 2023, and approved Yuviwel in February 2026 for children aged 2 and older with open growth plates.
- BioMarin's Voxzogo brand revenue rose 26 percent to USD 927 million in 2025, with the drug sold in 55 commercial markets and about 73 percent of brand revenue earned outside the United States, showing sustained uptake of targeted achondroplasia treatment.
- Targeted treatment is extending to hypochondroplasia, which MedlinePlus says may be about as common as achondroplasia. BioMarin's Phase 3 CANOPY-HCH-3 trial improved annualized growth velocity by 2.33 cm/year over placebo, reported in May 2026, and BioMarin has submitted an sNDA for the indication.
Market Challenges
- Setrusumab missed its fracture-rate primary endpoints in the Phase 3 Orbit and Cosmic trials in December 2025, leaving osteogenesis imperfecta without an approved targeted drug identified in the sources reviewed.
- Yuviwel's February 2026 approval is accelerated, so continued approval may depend on confirmatory trials verifying clinical benefit beyond growth velocity.
- Thanatophoric dysplasia occurs in 1 in 20,000 to 50,000 newborns and is usually fatal around birth, and no targeted therapy for it was identified.
- NICE had not issued guidance on vosoritide in the sources reviewed, with its appraisal for people aged 4 months and over still in development.
Opportunities
- Hypochondroplasia had no FDA- or EMA-approved therapy in May 2026, and BioMarin's sNDA positions Voxzogo for a potential 2027 launch as the first targeted treatment.
- Oral FGFR3-targeted drugs, including BridgeBio's infigratinib and Tyra Biosciences' TYRA-300, could appeal to families seeking alternatives to injections.
- Sequencing-based diagnosis could widen as the 2023 nosology links skeletal disorders to 552 genes, helping clinicians reach a molecular diagnosis earlier.
- Asia Pacific, which The Business Research Company expects to grow fastest in skeletal dysplasia drugs, may reward companies extending approvals beyond Japan.
Trends and Insights
Key market trends shaping the industry landscape
Weekly and oral dosing
High impactMid-termAchondroplasia treatment is moving from daily injections to weekly and oral options.
Insight: Yuviwel's once-weekly dosing and infigratinib's oral route may shift prescribing toward lower-burden regimens, which could pressure Voxzogo's position as new options reach patients.
Expansion beyond achondroplasia
Medium impactLong-termC-type natriuretic peptide drugs are being tested in other growth disorders.
Insight: BioMarin runs Phase 2 Voxzogo studies in idiopathic short stature, Noonan syndrome, Turner syndrome and SHOX deficiency, which could enlarge the treated population if results support filings.
From accelerated to full approval
Medium impactShort-termRegulators are reviewing confirmatory evidence for growth drugs.
Insight: The FDA's February 2027 action date on Voxzogo's full approval may test whether growth-velocity gains are accepted as clinical benefit, setting a reference point for Yuviwel.
Osteogenesis imperfecta setback
Medium impactMid-termTargeted therapy for brittle bone disease has stalled after Phase 3 results.
Insight: Setrusumab improved bone mineral density but missed fracture endpoints, which suggests regulators and payers may look for fracture reduction rather than density gains in osteogenesis imperfecta.
Segment Analysis
Market segmentation by type, diagnosis, treatment, end-user
Achondroplasia is the most common type of short-limbed dwarfism, occurring in 1 in 15,000 to 40,000 newborns according to MedlinePlus. It holds both approved targeted drugs identified in the sources reviewed, BioMarin's Voxzogo and Ascendis Pharma's Yuviwel. Hypochondroplasia, which MedlinePlus says may be about as common as achondroplasia, has no approved targeted therapy, although BioMarin has filed Voxzogo for it. Osteogenesis Imperfecta affects about 1 in 10,000 to 20,000 people, and bisphosphonates are used to raise bone mineral density. Thanatophoric Dysplasia occurs in 1 in 20,000 to 50,000 newborns, and affected infants are usually stillborn or die shortly after birth. Multiple Epiphyseal Dysplasia, at least 1 in 10,000 newborns in its dominant form, causes hip and knee pain and early-onset arthritis. No published source splits market value by type.
Geography Analysis
Regional market analysis
North America
The Business Research Company names North America the largest region in the skeletal dysplasia drugs market in 2025, so the ranking here rests on that publisher's assessment rather than on a measured regional share. The FDA approved Voxzogo in 2021 and Yuviwel on 27 February 2026, giving the United States two approved achondroplasia drugs. BioMarin reports that markets outside the U.S. produced about 73 percent of 2025 Voxzogo brand revenue, so the regional lead does not come from Voxzogo sales. The regional constraint is that both U.S. approvals are accelerated, and Voxzogo's full approval awaits an FDA action date of 28 February 2027.
Europe
The European Commission approved Voxzogo in August 2021, three months before the FDA, making it the first medicine approved in Europe for children with achondroplasia. Ascendis Pharma expected an EU decision on Yuviwel in the fourth quarter of 2026, and BridgeBio planned an MAA for infigratinib in the second half of 2026. No separate European skeletal dysplasia market size was identified in the sources reviewed. The regional constraint is uneven reimbursement: in England, NICE's appraisal of vosoritide remained in development after scoping began in March 2025.
Asia Pacific
The Business Research Company expects Asia-Pacific to be the fastest-growing region in the skeletal dysplasia drugs market, although no regional growth rate for the skeletal dysplasia market was identified in the sources reviewed, so the ranking rests on that assessment. Japan approved Voxzogo in June 2022 for children whose growth plates are not closed, with no lower age limit, before the U.S. extension to children under 5 in October 2023. No separate Asia Pacific market size was identified in the sources reviewed. The regional constraint is that no Asia Pacific approval of Yuviwel or infigratinib was identified in the sources reviewed.
Latin America
Brazil's ANVISA has approved Voxzogo for achondroplasia in children from 6 months of age whose epiphyses are not closed. No regional market size, revenue or growth figure was identified in the sources reviewed. The regional constraint is public funding: a vosoritide dossier dated September 2025 was submitted to CONITEC, Brazil's health technology assessment body, and coverage in the public system was not confirmed in the sources reviewed.
Middle East & Africa
Middle East & Africa has the least published evidence of the five regions, and no regional market size, revenue or growth figure was identified in the sources reviewed. None of the five Major Players discloses skeletal dysplasia sales in the region. The regional constraint is that no approval of Yuviwel or infigratinib in the region was identified in the sources reviewed.
Competitive Landscape
Key players and market positioning analysis
Skeletal dysplasia drug development centres on the FGFR3 and C-type natriuretic peptide pathways in achondroplasia, with osteogenesis imperfecta programmes further behind. No company publishes a share of the skeletal dysplasia market, so the order used here rests on approved products and development stage. BioMarin holds the established position, with Voxzogo brand revenue of USD 927 million in 2025 across 55 commercial markets, and it is pursuing hypochondroplasia and a longer-acting CNP, BMN 333. Ascendis Pharma gained FDA accelerated approval for once-weekly Yuviwel in February 2026 and awaits an EU decision. BridgeBio's oral infigratinib met its Phase 3 primary endpoint in February 2026, with NDA and MAA filings planned for the second half of 2026. Ultragenyx, with partner Mereo BioPharma, is analysing setrusumab data after the Phase 3 osteogenesis imperfecta trials missed their primary endpoints. Tyra Biosciences is testing the oral FGFR3-selective inhibitor TYRA-300 in the Phase 2 BEACH301 study. Competition therefore turns on dosing burden, growth effect and indication breadth, and positioning may shift as oral therapies seek approval.
Major Players
Leading companies in the market
Industry Developments
9 recorded developments
BridgeBio reported on 12 February 2026 that oral infigratinib met its primary endpoint in the Phase 3 PROPEL 3 achondroplasia trial, with a least-squares mean gain in annualized height velocity of 1.74 cm/year over placebo.
The FDA granted accelerated approval on 27 February 2026 to Ascendis Pharma's Yuviwel (navepegritide), a once-weekly injection for children aged 2 and older with achondroplasia and open growth plates. Its EU application remained under EMA review.
BioMarin reported in May 2026 that Voxzogo met its primary endpoint in the Phase 3 CANOPY-HCH-3 trial in hypochondroplasia, then submitted an sNDA. In July 2026 the FDA set a 28 February 2027 action date for converting Voxzogo to full approval in achondroplasia.
Tyra Biosciences opened its Phase 2 BEACH301 study of TYRA-300, an oral FGFR3-selective inhibitor, in children with achondroplasia in March 2025, after the FDA cleared its investigational new drug application in October 2024.
Ultragenyx and Mereo BioPharma reported on 29 December 2025 that setrusumab missed the fracture-rate primary endpoints of the Phase 3 Orbit and Cosmic trials in osteogenesis imperfecta, although both trials met bone mineral density secondary endpoints.
The FDA extended Voxzogo's accelerated approval to children under 5 on 20 October 2023, so the U.S. label now covers achondroplasia patients of all ages with open growth plates.
The 2023 revision of the Nosology of Genetic Skeletal Disorders, published in the American Journal of Medical Genetics, listed 771 entries linked to 552 genes and paired each condition with the gene it arises from.
Japan's Ministry of Health, Labour and Welfare approved Voxzogo in June 2022 for children with achondroplasia whose growth plates are not closed, with no lower age limit.
The European Commission approved BioMarin's Voxzogo (vosoritide) in August 2021, the first medicine approved in Europe for children with achondroplasia. The FDA followed with accelerated approval in November 2021 for children aged 5 and older with open growth plates.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Type
5.3 By Diagnosis
5.4 By Treatment
5.5 By End-User
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 BioMarin Pharmaceutical Inc.
9.2 Ascendis Pharma A/S
9.3 BridgeBio Pharma, Inc.
9.4 Ultragenyx Pharmaceutical Inc.
9.5 Tyra Biosciences, Inc.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2034
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
BioMarin Pharmaceutical Inc., Ascendis Pharma A/S, BridgeBio Pharma, Inc., Ultragenyx Pharmaceutical Inc. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.